Elimination of Ascorbic Acid following High-Dose Infusion in Prostate Cancer Patients: A Pharmacokinetic Evaluation

Abstract: Treatment with high-dose intravenous (IV) ascorbic acid (AA) is used in complementary and alternative medicine for various conditions including cancer. Cytotoxicity to cancer cell lines has been observed with millimolar concentrations of AA. Little is known about the pharmacokinetics of high dose IV AA. The purpose of the present study was to assess the basic kinetic variables in human beings over a relevant AA dosing interval for proper design of future clinical trials. Ten patients with...
metastatic prostate cancer were treated for four weeks with fixed AA doses of 5, 30 and 60 g. AA was measured consecutively in plasma and indicated first-order elimination kinetics throughout the dosing range with supra-physiological concentrations. The target dose of 60g AA IV produced a peak plasma AA concentration of 20.3 mM. Elimination half-life was 1.87 hr (mean, SD ± 0.40), volume of distribution 0.19 L/kg (SD ±0.05) and clearance rate 6.02 L/hr (100mL/min). No differences in pharmacokinetic parameters were observed between weeks/doses. A relatively fast first-order elimination with half-life of about 2 hr makes it impossible to maintain AA concentrations in the potential cytotoxic range after infusion stop in prostate cancer patients with normal kidney function. We propose a regimen with a bolus loading followed by a maintenance infusion based on the calculated clearance.

Clinicaltrials.gov: NCT01080352

In the 1970s, Cameron, Campbell and Pauling reported prolonged overall survival after treatment with high-dose ascorbic acid (AA) in patients with advanced cancer disease [1,2]. The methodology in these two studies was criticized, and the results were not confirmed in two subsequent randomized, controlled trials with oral AA [3,4]. Treatment with intravenous (IV) AA has continued in complementary and alternative medicine and is widely used today [5].

Cell culture studies and animal models have shown that AA in millimolar extracellular concentrations are cytotoxic to cancer cells without apparent toxicity for normal cells [6–11]. From oral intake, plasma AA concentrations are tightly controlled by a saturable gastrointestinal absorption and a saturable renal tubular reabsorption. Despite daily oral gram doses of AA, the upper plasma level is ~220 µM [12,13]. To achieve the >100-fold higher concentrations required for potential cytotoxicity to cancer cells, AA must be administered intravenously. Very little data have been published on the pharmacokinetics of high-dose AA, although AA infusions have been used in alternative medicine for decades. One phase I trial was designed as a dose-escalation trial with 5-7 patients in 4 groups [14], and within the last year two additional studies have been published with 14 and 17 patients,

This article is protected by copyright. All rights reserved.
respectively [15,16], with only one presenting pharmacokinetic data like half-life (T½) and clearance [16]. The purpose of the present study was to evaluate the basic pharmacokinetics of high-dose AA.

**Material and Methods**

**Study design**

Patients were consecutively recruited from an ongoing non-comparative-, singe-centre, phase II trial, investigating efficacy and safety of IV AA in patients with metastatic castration-resistant prostate cancer. Patients were recruited from the outpatient urology clinic at Copenhagen University Hospital Herlev, Copenhagen, Denmark.

**Patient eligibility**

All patients signed informed consent forms. The trial was approved by the Regional Ethics Committee (H-C-2009-018) and the Danish Health and Medicines Authority (2612-3978), registered (Eudra-CT 2008-008692-33 / NCT01080352), the Danish Data Protection Agency (2007-58-0015/750.19-15) and followed the current Guideline for Good Clinical Practice issued by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use and the Declaration of Helsinki.

Eligibility criteria included adenocarcinoma of the prostate with a least one metastatic lesion on bone- or CT scan; ongoing androgen deprivation therapy with a castration level of testosterone (<1.7 nmol/L); disease progression (prostate-specific antigen or on imaging) as defined by the Prostate Cancer Working Group 2 (PCWG-2) [17]; no prior chemotherapy; Eastern Cooperative Oncology Group (ECOG) performance 0-2. Key exclusion criteria were significant renal impairment (creatinine >200 µmol/L); significant cardiac disease (NYHA >2, CSS >2, recent myocardial infarction (less than 6 months)); haemochromatosis, glucose-6-phosphate dehydrogenase deficiency or history of oxalate renal stones.
**Patient characteristics**

Twelve consecutive patients from the main trial were invited to participate in the present study. Two did not wish to participate due to the time burden. All patients (n=10) were male Caucasians diagnosed and followed in our clinic. Detailed baseline characteristics are listed in table 1. Patient characteristics were collected during a full medical examination one week prior to study week #1. Body surface area (BSA) was calculated with the DuBois formula [18], extracellular volume (ECV) was calculated with the Bird formula [19] and estimated glomerular filtration rate (eGFR) was calculated with the ‘MDRD formula’ [20]. Creatinine clearance was measured from plasma creatinine concentration and 24-hr urinary creatinine excretion.

**Intervention**

Patients received three different doses of AA in the four-week study period. Doses, infusion rates and volumes are shown in table 2. The main trial target dose of 60 g was reached in week 3 and continued once a week until initial efficacy evaluation after twelve weeks; hence the interventions in week 3 and 4 were identical. AA was administered via an infusion pump to an IV catheter in the proximal forearm. AA for infusion was batch-produced by the ‘Capitol Region Pharmacy’ (Good manufacturing practices (GMP) certified governmental pharmacy). Each mL of infusion concentrate contained 562.4 mg sodium ascorbate (equal to 500 mg of ascorbic acid). Just before infusion, the concentrate was dissolved in 5% isotonic glucoses or sterile water. Osmolarity was measured to 337 mOsm and 623 mOsm, respectively. Drug stability was checked once in the study period.

Patients were under observation by study personnel during and after the infusion. Thirty minutes after the infusion, vital signs were measured and blood was drawn to screen for hemolysis. All adverse events (AE) were scored by Common Terminology Criteria for Adverse Events v4.03 (CTCAE) [21].

Patients were provided a daily 500 mg oral dose of AA starting the day after the first infusion to avoid a hypothesized rebound deficiency following high-dose AA infusions [22].

This article is protected by copyright. All rights reserved.
Sample collection and analysis

Blood samples were collected from the cubital vein in the contra lateral arm of the infusion. Samples were collected at the following times: 1) before infusion (-60/-30 min.); 2) at 50% of volume infused (-30/-15 min.); 3) at infusion stop (0 min.); 4) after infusion stop (+ 30, 60, 120, 180 and 240 min.).

Samples to be analysed for AA were taken and pre-treated as follows: Whole blood was collected using a 6-mL ‘GBO Vacuette’ K$_3$EDTA-coated blood collection tube [23]. Immediately after collection 1.5 mL of blood was transferred to a microcentrifuge tube and centrifuged at 16000 x g for 2 min. at 4°C. Plasma (500 µL) was then transferred into a microcentrifuge tube containing 500 µL of cold (4°C) 10% meta-phosphoric acid containing 2mM EDTA. The mixture was vortexed for 10 sec. and centrifuged at 16000 x g for 1 min. at 4°C. The protein-free supernatant was collected and stored at -80°C until analysis. Stability of the samples under these conditions is at least five years [24]. All samples from each individual were analysed together using high-performance liquid chromatography with coulometric detection as described previously [25]. The within- and between day coefficients of variation are less than 1.5 and 3.5%, respectively, and detection limit less than 1 µmol/L. AA samples were stored for 5.9 months (mean; range 1.8-9.9) before analysis.

Hemoglobin (Hb) was measured at each time point to correct for hemodilution during the infusion, and the plasma AA measured was multiplied with the ratio (Hb$_{time}$/Hb$_{baseline}$). Two measurements of AA and three of hemoglobin were not included in the analysis due to sample coagulation or analytical error.

Modelling

The AA plasma concentration versus time curve showed exponential decay after infusion was stopped, indicating first-order elimination kinetics. It was therefore possible to calculate elimination, elimination half-life (T½), volume of distribution (V$_d$) and clearance of plasma AA. AUC was calculated using the trapezoidal rule. We used the ratio of AUC in the post-infusion phase over the

This article is protected by copyright. All rights reserved.
total AUC, to compensate for elimination prior to infusion stop. $V_d$ was calculated as AUC-ratio adjusted dose over modelled $C_{max}$.

**Results**

All ten patients received the planned four doses of AA without any severe adverse events. One episode of transient arterial hypertension immediately after the infusion (CTCAE Grade 2) and two unrelated AEs (CTCAE Grade 1) were observed. The maximal infused dose of 60 g was equal to 723.3 mg/kg (median, range: 576.9-952.4) and 29.79 g/m$^2$ (median, range: 27.21-34.38). The infusion of 5, 30 and 60 g of AA resulted in mean peak AA concentration of 1.9, 12.5, 19.5 and 21.0 mmol/L, respectively, as shown in fig. 2. Without correction for hemodilution, the mean peak concentrations were 1.8, 11.7, 18.2 and 19.3 mmol/L, respectively. Pre-infusion baseline AA showed a non-significant rise from week 1 of 63.2 to 90.5 µM in week 4 ($p=0.18$).

The $C_{max}$, AUC, elimination $T_{1/2}$ and clearance are presented in table 3. Elimination $T_{1/2}$ was 1.87 hr (mean, SD ± 0.40) and $V_d$ was 0.19 L/kg (SD ±0.05). Mean ECV was 15.9 L (SD±1.5) which was similar to $V_d$ multiplied by weight with a mean of 15.6 L (SD±4.2). Clearance was 6.02 L/h (SD±1.91) and standardized 5.20 L/h/1.73m$^2$ (SD±1.59). There were no significant differences in the pharmacokinetic parameters between weeks including the AUC/dose ratio.

**Discussion**

The primary objective of our study was to collect pharmacokinetic information on high-dose AA infusion. The trial had a target dose of 60 g AA, which produced a peak plasma AA concentration of 20.3 mM. We found first-order elimination kinetics with a very short half-life of 1.87 hr (112 min), a $V_d$ of 0.19 L/kg which was similar to ECV and an AA clearance rate of 6.02L/h (100mL/min).

Following visual examination of each individual concentration versus time curve, it was concluded that the pattern justifies the use of one compartment first-order kinetics in the calculations because of exponential decay as evidenced by linearity of the log plasma concentration versus time curves.
Urine samples were not collected during infusion and elimination and consequently, the actual excretion was not assessed, which should be done in future studies. All patients received fixed doses of 5, 30 and 60 g of AA. Three existing studies have used either a fixed dose [15] or dose adjusted by weight [14] or surface [16]. In the present study, $V_d$ was found to be similar to ECV, while dose scaling for ECV size is not supported by our data as shown in the inset in fig. 2. Thus, in a linear regression model, ECV was a significant predictor of $C_{max}$, but the model was completely dependent on data from one outlier, and removal of those from the model resulted in a $C_{max}$ independent of ECV volume which confirms the visual impression. Androgen deprivation therapy induces metabolic changes, which is also seen by the relatively high mean BMI of the patients. The outlier had the lowest body mass and BMI of all individuals, so it is not possible to determine whether the very high concentrations achieved are due to a different body composition or due to other factors unique to the patient.

Stephenson et al. have reported a half-life between 1.7-2.5 hr after 30-110g IV AA/m$^2$ [16], which is comparable to the findings of the present study. Graumlich et al. [26] studied AA pharmacokinetics within the normal physiological range and reported a clearance rate of 10.9 L/hr with net tubular excretion as a contributor in the AA concentration range just above physiological level. When plasma concentrations approaches physiological levels, the elimination follows a multi-compartmental model [26]. In the present study, the calculated creatinine clearance is nearly identical to the AA clearance. The interpretation is therefore that renal filtration accounts for most of the AA clearance, and other elimination mechanisms apparently play a minor role in the supra-physiological plasma range. Although T½ was similar, the clearance found in the present study normalized to surface area but was slightly higher than the clearance observed by Stephenson et al. [16]. Apparently their calculation does not correct for AA lost during the infusion phase and thereby underestimating clearance, while the present study may slightly overestimate clearance when correcting for AA elimination during infusion. Using the actual measured peak AA instead of model $C_{max}$ in clearance the calculations results in a non-significant reduction in clearance of about 1 L/hr (data not shown).
Graumlich et al. [26] estimated the volume of the central compartment to 11.8 L in their model, which is comparable to $V_d$ of 15.6 L found in the present study, also taking into account the nearly ten kilogram larger bodyweight of the individuals in our study.

Efficacy of AA in clinical medicine has not been established. AA has been reported as an effective ex vivo cytotoxic substance in a large panel of tumour cell lines[8–11], although the high inhibitory concentration may make it less probable to succeed through the drug developmental phases[27]. Cytotoxicity was not evident in normal cells at ascorbate concentrations exceeding 20 mM [8], in contrast to numerous cancer cell lines, which leaves as possible therapeutic window to be investigated further. The concentration of ascorbic acid varies between tissues [28]. Endothelial cells [29] and white blood cells have been shown to be able to accumulate AA in concentrations above 1 mM, but the uptake mechanism saturates above 100 mg of AA daily [30]. The consequence of this accumulation in relation to anti-tumour activity is unknown.

The detailed mechanism by which AA exerts its cytotoxicity remains to be established. Data from the NCI60 panel does not provide a good fingerprint of leads to follow in order to unveil the mechanism of action [11]. Chen et al. proposed that the cytotoxic effects may be mediated through the Reactive Oxygen Species hydrogen peroxide ($H_2O_2$) formation rather than by AA itself [31]. Thus, they suggested that $H_2O_2$ is dose-dependently generated in the extracellular environment from the ascorbyl radical and a protein-centered metal [32], which could be ferritin secreted by the tumour cells [33]. $H_2O_2$ generation displayed a linear relationship with the formation of the AA radical. Although $H_2O_2$ might be able to reach the cancer cells by diffusion, in order to reach intracellular targets of the cancer cell, it has to pass the cell membrane. Simple passive diffusion of the polar $H_2O_2$ across the lipid bilayer membranes should be limited as for water, but the transfer might be facilitated by and dependent on aquaporins [34].

In addition to the concentration of AA, the tumour cell count and exposure time also plays an important role for the cytotoxicity of AA. $H_2O_2$ degradation rate and toxicity of AA are dependent on
the number of cells in *in vitro* experiments [33], which could imply a lower penetration of AA into cell formations or the generation of a protective microenvironment when cell count (or tumour size) reaches a certain level [35]. Only a limited number of *in vitro* studies have used short AA exposure time, which can be comparable to the setting in human beings following a bolus of intravenous AA. Venugopla *et al.* have reported an inverse relationship between cytotoxic AA concentration levels and incubation time in urologic cancer cell lines [36], and similar trends have been reported by Chen *et al.* [37]. Exposure time for cytotoxicity to be effective *in vivo* needs to be evaluated further in future studies.

Three studies have given some implications of efficacy *in vivo*, with doses of daily 1g/kg [10] and 4g/kg [7,8] intraperitoneally, although the latter by far exceeds what has been used in human phase I trials. AA was shown to reduce tumour size in xenograft models (athymic, nude mice) of three different cell lines [8] and to induce some degree of cytostasis in a syngenic rat prostate cancer model [7] and a syngenic hepatocarcinoma mouse model [10]. Only one of the studies provides data to calculate valid response parameters of efficacy (change in tumour volume in treated versus controls; %T/C), but from figures in the papers, it does not appear to be <40% which is a traditionally used cut-off for efficacy [38].

Data from the present study can be used to calculate a bolus-loaded target plasma concentration, which can be maintained during a defined timeframe by using a calculable maintenance infusion. If the AA bolus is not delivered in a central venous catheter, the osmotic activity of AA will require it to be combined with a large fluid load. Dissolved in a suitable vehicle to around 600 mOsm, a bolus infusion rate of 1g/min is reasonable with the aim of producing high AA plasma concentrations and concurrently avoiding local vascular reactions due to osmolality. The maintenance infusion rate and elimination rate are equal in steady state, which makes it possible to calculate maintenance dose: 

*dosing rate = clearance × target concentration* [39]. Based on our data, a bolus infusion of 60 g (at 1g/min) followed by a maintenance infusion of 21.1g/hr will achieve a plasma steady state.
concentration of AA above 20 mM; continuing to a specified time. No trial has used a bolus maintenance regimen, and despite the apparent atoxic profile of AA in previous trials, it has not been examined if the drug itself or volume induced electrolyte disturbances may produce adverse events over time.

We conclude that with constant infusion of AA in prostate cancer patients with normal kidney function, it is possible to achieve a desired steady state plasma concentration of AA in the range of 1.5-37.8 mM from doses up to 60 g as long as the infusion lasts. The relatively fast first-order kinetics, evidenced by an elimination half-life of about 2 hr, makes it impossible to maintain such high AA concentrations after infusion stop.

Acknowledgements

The study was funded by the Foundation of Kirsten and Freddy Johansen.


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.


**TABLES AND FIGURES**

<table>
<thead>
<tr>
<th></th>
<th>Median</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age [years]</td>
<td>72.8</td>
<td>54.2 - 87.2</td>
</tr>
<tr>
<td>Weight [kg]</td>
<td>83</td>
<td>63 - 104</td>
</tr>
<tr>
<td>BMI [kg/m²]</td>
<td>27.8</td>
<td>21.3-33.2</td>
</tr>
<tr>
<td>Body surface area (DuBois) [m²]</td>
<td>2.01</td>
<td>1.75 - 2.20</td>
</tr>
<tr>
<td>eGFR [L/hr/1.73]</td>
<td>4.62</td>
<td>3.58-5.18</td>
</tr>
<tr>
<td>GFR estimate (creatinine clearance) with body surface correction [L/hr/1.73m²]</td>
<td>5.14</td>
<td>1.43*-6.59</td>
</tr>
</tbody>
</table>

This article is protected by copyright. All rights reserved.
Table 1. Patient characteristics measured/colllected with a full medical examination in the week prior to week #1. Estimated glomerular filtration rate (eGFR) was calculated with the Modification of Diet in Renal Disease (MDRD) equation [20].

*One extreme outlier with very small urine sample, eGFR normal = 4.96 L/hr

<table>
<thead>
<tr>
<th>Week</th>
<th>AA [grams]</th>
<th>Vehicle</th>
<th>Total volume [mL]</th>
<th>Infusion rate [g/min]</th>
<th>Infusion time [min]</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>5</td>
<td>5% isotonic glucose</td>
<td>510</td>
<td>0.17</td>
<td>30</td>
</tr>
<tr>
<td>#2</td>
<td>30</td>
<td>Sterile water</td>
<td>500</td>
<td>1</td>
<td>30</td>
</tr>
<tr>
<td>#3</td>
<td>60</td>
<td>Sterile water</td>
<td>1000</td>
<td>1</td>
<td>60</td>
</tr>
<tr>
<td>#4</td>
<td>60</td>
<td>Sterile water</td>
<td>1000</td>
<td>1</td>
<td>60</td>
</tr>
</tbody>
</table>

Table 2. Treatment scheme. Dose of ascorbic acid, solvent and infusion rate/time.

<table>
<thead>
<tr>
<th>Week 1 (5Gr)</th>
<th>Week 2 (30Gr)</th>
<th>Week 3 (60Gr)</th>
<th>Week 4 (60Gr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; [µmol/L]</td>
<td>n, range</td>
<td>C&lt;sub&gt;max&lt;/sub&gt; [µmol/L]</td>
<td>n, range</td>
</tr>
<tr>
<td>1852 ± 386 (n=9), 1495-2775</td>
<td>12525 ± 3404 (n=10), 6271-16814</td>
<td>19456 ± 6745 (n=10), 14789-37767</td>
<td>21055 ± 5039 (n=10), 17206-34524</td>
</tr>
<tr>
<td>Dose / kg median</td>
<td>range</td>
<td>Dose / kg median</td>
<td>range</td>
</tr>
<tr>
<td>60.3</td>
<td>48.1-79.4</td>
<td>361.6</td>
<td>288.5-476.2</td>
</tr>
<tr>
<td>Dose / m² median</td>
<td>range</td>
<td>Dose / m² median</td>
<td>range</td>
</tr>
<tr>
<td>2.48</td>
<td>2.27-2.87</td>
<td>14.90</td>
<td>13.61-17.19</td>
</tr>
<tr>
<td>T½ [min]</td>
<td>±SD</td>
<td>T½ [min]</td>
<td>±SD</td>
</tr>
<tr>
<td>99.6 ± 21.0</td>
<td>114.7 ± 27.1</td>
<td>118.1 ± 24.0</td>
<td>117.1 ± 21.3</td>
</tr>
<tr>
<td>AUC [h mM]</td>
<td>±SD</td>
<td>AUC [h mM]</td>
<td>±SD</td>
</tr>
<tr>
<td>3.59 ± 1.05</td>
<td>24.75 ± 8.29</td>
<td>48.38 ± 16.7</td>
<td>49.76 ± 14.8</td>
</tr>
<tr>
<td>% of AUC before infusion stop</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.7%</td>
<td>15.0%</td>
<td>24.0%</td>
<td>24.3%</td>
</tr>
<tr>
<td>V&lt;sub&gt;d&lt;/sub&gt; [L/kg]</td>
<td>±SD</td>
<td>V&lt;sub&gt;d&lt;/sub&gt; [L/kg]</td>
<td>±SD</td>
</tr>
<tr>
<td>0.19 ± 0.03</td>
<td>0.18 ± 0.09</td>
<td>0.19 ± 0.03</td>
<td>0.18 ± 0.03</td>
</tr>
<tr>
<td>Clearance [L/h]</td>
<td>±SD</td>
<td>Clearance [L/h]</td>
<td>±SD</td>
</tr>
<tr>
<td>6.84 ± 2.11</td>
<td>5.56 ± 1.85</td>
<td>5.92 ± 2.00</td>
<td>5.75 ± 2.00</td>
</tr>
</tbody>
</table>

Table 3. Calculated pharmacokinetic data by week number. C<sub>max</sub>: Peak ascorbic acid concentration. T½: Half-life. AUC: Area under the curve. V<sub>d</sub>: Volume of distribution
Fig. 1. Concentration of ascorbic acid in plasma during infusion and elimination.
Fig. 2. Peak plasma ascorbic acid concentration ($C_{\text{max}}$). Inset: $C_{\text{max}}$ after the 60-g target dose (week 3 + 4) correlated to extracellular volume (ECV) in litre.